These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28118650)

  • 21. Pembrolizumab shows promise in lung cancer.
    Cleghorn S
    Lancet Respir Med; 2015 Jun; 3(6):429. PubMed ID: 25935769
    [No Abstract]   [Full Text] [Related]  

  • 22. Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
    Morgensztern D; Herbst RS
    Clin Cancer Res; 2016 Aug; 22(15):3713-7. PubMed ID: 27252413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biological follow-up of patients with HIV treated with anti-PD-1 or anti-PD-L1 for non-small cell bronchial carcinoma: A task group proposal].
    Guihot A; Cadranel J; Lambotte O; Lavolé A; Autran B; Spano JP
    Rev Mal Respir; 2016 Jun; 33(6):419-21. PubMed ID: 27140903
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
    Winkler JK; Schneiderbauer R; Bender C; Sedlaczek O; Fröhling S; Penzel R; Enk A; Hassel JC
    Br J Dermatol; 2017 Feb; 176(2):498-502. PubMed ID: 27061826
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
    Leventakos K; Mansfield AS
    BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First Anti-PD-L1 Drug Approved for NSCLC.
    Cancer Discov; 2016 Dec; 6(12):OF1. PubMed ID: 27920140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1-targeted immunotherapy: recent clinical findings.
    Brahmer JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
    [No Abstract]   [Full Text] [Related]  

  • 29. PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Bagley SJ; Bauml JM; Langer CJ
    Clin Adv Hematol Oncol; 2015 Oct; 13(10):676-83. PubMed ID: 27058572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
    Kang SP; Gergich K; Lubiniecki GM; de Alwis DP; Chen C; Tice MAB; Rubin EH
    Ann Oncol; 2017 Jun; 28(6):1388-1398. PubMed ID: 30052728
    [No Abstract]   [Full Text] [Related]  

  • 32. The small-cell lung cancer drug market.
    Dawkins JBN; Webster RM
    Nat Rev Drug Discov; 2020 Aug; 19(8):507-508. PubMed ID: 32235872
    [No Abstract]   [Full Text] [Related]  

  • 33. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy.
    Basin S; Perrin J; Michot JM; Lambotte O; Cauquil C
    Eur J Cancer; 2021 Mar; 145():230-233. PubMed ID: 33517201
    [No Abstract]   [Full Text] [Related]  

  • 35. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
    Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM
    J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis.
    Uprety D; Arjyal L; Vallatharasu Y; Bista A; Wittchow RJ; Marinier DE
    Clin Lung Cancer; 2019 Sep; 20(5):e552-e554. PubMed ID: 31285178
    [No Abstract]   [Full Text] [Related]  

  • 37. A rapid response to pembrolizumab in a patient with metastatic melanoma.
    Bayo Calero J; Aviñó Tarazona V
    Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
    Mishra T; He G; Sreeram K; Rauf M; Subahi A; Hazem M
    Am J Ther; 2019; 26(5):e626-e627. PubMed ID: 30277909
    [No Abstract]   [Full Text] [Related]  

  • 39. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
    Hammer M; Bagley S; Aggarwal C; Bauml J; Nachiappan AC; Simone CB; Langer C; Katz SI
    Curr Probl Diagn Radiol; 2019; 48(2):142-147. PubMed ID: 29573843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American Association of Cancer Research Showcases Immunotherapy Advances.
    Brower V
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.